Cabergoline

• Cabaser

Cabergoline is a selective dopamine receptor agonist. This agent is highly specific in its actions, with a strong affinity for the dopamine 02 receptor, and a low affinity for dopamine 01, A1-adrenergic, A2-adrenergic, 5-HT1serotonin, and 5-HT2-serotonin receptors. Its main clinical use is for the treatment of hyperprolactinemia, or the hypersecretion of prolactin from lactotropes in the anterior pituitary (pituitary tumor is a common cause of this disorder). It is also applied in the management of Parkinson's disease. Cabergoline effectively inhibits prolactin secretion, which it does by mimicking the actions of dopamine on the 02 receptor (dopamine normally serves as negative feedback for prolactin release). As a targeted agonist of the dopamine 02 receptor,cabergoline should not affect other pituitary hormones like growth hormone (GH), luteinizing hormone (LH), corticotrophin (ACTH), or thyroid stimulating hormone (TSH).

The most common side effects reported with cabergoline use include headache, nausea, and vomiting. Other potential side effects include (but are not limited to) constipation, dry mouth, abdominal pain, diarrhea, dizziness, vertigo, fatigue, anxiety, anorexia, malaise, depression, insomnia, hot flashes, heart palpitations, hypotension, breast pain, and acne, however nausea and headache were the most prominent side effects.